Derma Pella Pharmaceuticals

What Derma Pella Pharmaceuticals does

Derma Pella Pharmaceuticals (legal entity: Pella Pharmaceutical co.) is a Jordan-based pharmaceutical manufacturer founded in 2009, with production operations beginning in January 2011 from its manufacturing facility in Al Hassan Industrial City. The company specializes in topical dermatological formulations across three product categories: pharmaceuticals (prescription treatments for acne, eczema, fungal infections, and hyperpigmentation), cosmeceuticals (sunscreens, anti-aging creams, moisturizers, and hair care), and medical devices (wound care, oral care, intimate care, and personal lubricants), offering approximately 35+ distinct products.

The company's core technology is built around formulation and process development for topical dosage forms (creams, gels, ointments, balms, foams, and solutions), supported by in-house analytical method development, validation, physicochemical characterization, stability studies, and bioequivalence study management. Manufacturing is conducted at a single site that holds JFDA approval, GMP certification, ISO 9001:2015 for quality management, and ISO 13485:2016 for medical devices, with country-specific registrations in Sudan and the GCC. R&D is supplemented by a cooperation agreement with Jordan University of Science and Technology signed in February 2022.

The business model combines branded product sales distributed through independent distributors in 20+ countries spanning Asia, Africa, Europe, the Middle East, and North America, direct-to-consumer e-commerce via derma-pella.com, and contract manufacturing services, the last of which was launched via a strategic agreement with Deef Pharmaceutical Industries in Saudi Arabia in October 2024 to expand production capacity and regional presence. Pricing is not publicly disclosed; customers are directed to contact the company or purchase through authorized distributors.

Name

Derma Pella Pharmaceuticals

Legal name

Pella Pharmaceutical co.

Website

https://dermapharma.jo

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

51–100 employees

Short description

Derma Pella Pharmaceuticals is a Jordan-based manufacturer founded in 2009 that produces dermatological pharmaceuticals, cosmeceuticals, and medical devices for distribution across 20+ international markets via a partner network and direct e-commerce.

Ownership category

akta.pro rank

Product category

Dermatological Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Soap and Cleaning Compound Manufacturing (32561), Health and Personal Care Retailers (456)

SIC

Perfumes, Cosmetics & Other Toilet Preparations (2844), Soap, Detergents, Cleang Preparations, Perfumes, Cosmetics (2840), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Dermatology & Aesthetics Pharmaceuticals (HLAIAAAK)

akta.pro secondary industries

Dermocosmetics & Medical-Grade Skincare (CRABAAAF), Dermatology & Topical Skin Treatments (HLAIADAE), Dermatology Specialty Pharmaceuticals (HLAIACAL)

Keywords

• Dermatological pharmaceuticals
• Topical skin care
• Cosmeceutical manufacturing
• Medical device dermatology
• Prescription skincare

Headquarters

HQ city

Amman

HQ country

Jordan

HQ region

Middle East

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Supply Chain, Personnel, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Products Sales: Sale of prescription and over-the-counter pharmaceutical products for dermatological conditions including eczema, acne, and fungal infections
2. Cosmeceutical Products Sales: Sale of cosmeceutical products including sunscreens, moisturizers, anti-aging creams, and skin brightening products
3. Medical Devices Sales: Sale of medical devices including wound care products, oral care solutions, and personal care devices
4. Contract Manufacturing: Strategic contract manufacturing services for Deef Pharmaceutical Industries in Saudi Arabia to increase production capacity

Go-to-market motion1 record

Distribution channels3 records

Marketing channels3 records

Core offering

Derma Pella Pharmaceuticals manufactures and sells topical dermatological products across three categories: pharmaceuticals (prescription treatments for acne, eczema, hyperpigmentation, and fungal infections), cosmeceuticals (sunscreens, anti-aging creams, moisturizers, hair care and intimate care), and medical devices (head-lice treatment, oral mucosal gels, wound care, personal lubricants, nasal care). Products are produced at a GMP, ISO 9001:2015 and ISO 13485:2016 certified facility in Al Hassan Industrial City, Jordan, and sold to end customers through authorized international distributors and a direct e-commerce storefront, with additional contract manufacturing services.

Product overview

Derma Pella Pharmaceuticals operates as a pharmaceutical and cosmeceutical manufacturer with three main product categories: Pharmaceuticals (prescription treatments for skin conditions), Cosmeceuticals (advanced skincare products including sunscreens, moisturizers, and specialty creams), and Medical Devices (therapeutic devices for dermatological and personal care applications). The company offers topical treatments for conditions including acne, eczema, melasma, fungal infections, hair loss, and wound care, as well as sunscreens and anti-aging products. Products are distributed globally through a network of international distributors across Asia, Africa, Europe, and North America.

Differentiator

Problem solved

Functional benefit

Products and services

• Eramax-mild Gel Acne treatment gel with Erythromycin 4% and tretinoin 0.025%, used for treating Acne vulgaris and its scars.
• Tacrus Ointment Fast-acting ointment containing Tacrolimus monohydrate 0.1% for moderate to severe atopic dermatitis (eczema).
• Aquax-H Cream Eczema relief cream with Hydrocortisone 17-butyrate 0.1% for mild to moderate atopic dermatitis and skin irritation.
• Spotex Gel Antibiotic gel with Erythromycin 4% for treating acne vulgaris and bacterial skin infections.
• Triderma Cream Triple-combination cream with Hydroquinone 4%, Tretinoin 0.05% and Fluocinolone acetonide 0.01% for melasma and hyperpigmentation.
• Florexa Cream Eflornithine HCl 13.9% cream for treating facial hirsutism in women and enhancing laser hair removal efficacy.
• Ticozal Oral Gel Miconazole 2% flavored oral gel for treating fungal infections of the mouth, throat and gullet.
• Ticozal Cream Topical cream with Miconazole Nitrate 2% for treating skin and nail fungal infections.
• Acnipare Gel Adapalene 0.1% gel (third-generation topical retinoid) for mild to moderate acne vulgaris.
• Adacline Gel Benzoyl peroxide 2.5% gel that works synergistically to combat acne and regulate sebum production.
• Photoblock Cream SPF 50+ SPF 50+ family sunscreen providing maximum UVA and UVB protection.
• Photoblock Gel SPF 50+ SPF 50+ sunblock gel for oily and acne-prone skin with RONACARE AP antioxidant molecules.
• Photoblock Plus SPF 50+ Two-in-one sunscreen and anti-aging product with SPF 50+ and RONACARE AP antioxidant molecules.
• Photoblock Foam SPF 50 Fast-acting water-resistant sunscreen foam for sensitive skin, free from preservatives, fragrance and alcohol.
• Derma Pella Sunscreen Advance SPF 50+ SPF 50+ cream-gel sunscreen with UVA/UVB filters for all skin types, fast absorbing with matte finish.
• Derma Pella Under Eye Gel Under-eye treatment containing Haloxyl 2% and Micro Hyaluronic Acid to reduce dark circles and tired appearance.
• Derma Pella Luminous Cream Instant brightening cream with Niacinamide, Adenosine and Beta-glucan, also used as makeup base.
• Aquax Cream Fragrance-free family moisturizer with white petrolatum jelly and mineral oil.
• Sorafine Cremogel Non-comedogenic moisturizing cremogel with jojoba oil and beeswax for oily, acne-prone skin.
• Derma Pella Acne Care Acne care gel with Salicylic acid, Tea tree oil and Niacinamide to treat and prevent breakouts.
• Derma Pella Hand and Nail Cream Hand and nail cream with glycerin, shea butter, jojoba oil, hyaluronic acid and panthenol.
• Mostal Foam Daily-use hair foam with caffeine, Redensyl, Procyanidin B2 and Betaine to reduce hair loss and support hair growth.
• Aquax Plus Foam Moisturizing foam with 10% Urea for repairing damaged and dry skin.
• Delicate Care Ointment Fragrance-free, hormone-free and alcohol-free daily care ointment for sensitive intimate areas.
• Derma Pella Intimate Shave 2-in-1 intimate shave cream with shea butter, jojoba oil, aloe vera and other soothing agents to prevent razor bumps and moisturize.
• Cornex Gel Salicylic acid 16.7% and lactic acid 16.7% skin solution for treating corns and warts, packaged in a nozzle tube for accurate application.
• Delice Solution Dimethicone head-lice treatment that eradicates 96% of lice and nits within 10 minutes, safe for adults and children.
• Gengicure Gel Hyaluronic acid 0.2% oral gel that reduces pain and promotes healing of oral mucosal ulcers.
• Gengicure Hemogel Tranexamic acid 8% oral gel for maintenance of gingival-periodontal condition.
• Gengicure Solution Dexpanthenol 5% oral solution that relieves discomfort and accelerates healing of oral sores and oral mucositis.
• Derma Glide Gel Water-based personal lubricant gel compatible with condoms and matched to vaginal pH.
• Derma Pella Wound-Eaz Wound and burn cream with cetrimide, chlorhexidine and hyaluronic acid for disinfection and accelerated healing.
• Nasal Care Ointment Panthenol 5% nasal healing ointment for hydrating and healing damaged nasal mucosa, including isotretinoin-induced dryness.
• Osto-aid Cream Muscle and joint pain relief cream with glucosamine sulfate, MSM, emu oil and arnica montana extract.
• Contract Manufacturing Services Strategic contract manufacturing services provided to Deef Pharmaceutical Industries (Saudi Arabia) to increase production capacity and expand into the Saudi market and neighboring markets.

Quantifiable outcome

• Delice Solution eradicates 96% of lice and nits after 10 minutes of single use
• +1 more outcomes

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered core.

• Deef Pharmaceutical IndustriescoreStrategic or Co-development Partner · 8 October 2024Strategic contract manufacturing agreement signed on October 8, 2024. The partnership leverages the expertise of both companies and Deef Pharmaceutical Industries' presence in the Saudi market and neighboring markets. This agreement is intended to increase production capacity to meet growing demand and expand presence in neighboring countries.
• Jordan University of Science and TechnologycoreStrategic or Co-development Partner · 10 February 2022Cooperation agreement signed on February 10, 2022 between JUST and Pella Pharmaceuticals. The agreement aims to enhance cooperation in pharmaceutical industries, including exchange of scientific expertise and applied research, supervision and R&D, analytical studies, and utilization of technical capabilities and scientific equipment in pharmaceutical industries. Signed by Vice President Dr. Suhad Al-Jundi and General Manager Mr. Bashar Batayneh.

Scale indicators4 records

Recent moves5 records

Expansion highlights5 records

Broad incumbents

• Galderma: Global dermatology-specialty pharmaceutical company with Rx and aesthetic dermatology products (acne, rosacea, eczema, aesthetic injectables). Comparable as the category leader in dermatology Rx that Derma Pella's branded generics compete against for dermatologist mindshare and pharmacy shelf-space.
• Almirall: European specialty pharmaceutical company focused on dermatology (eczema, acne, actinic keratosis) with global commercial reach. Comparable as a mid-size dermatology specialty player whose business model of branded Rx + medical device dermatology closely mirrors Derma Pella's three-pillar structure.
• L'Oréal Dermatological Beauty (La Roche-Posay / Vichy): Global dermatological beauty division operating La Roche-Posay, Vichy, CeraVe, and SkinCeuticals — large cosmeceutical brands sold through pharmacies worldwide. Directly comparable for Derma Pella's Photoblock SPF line, anti-aging, and moisturizer SKUs competing for the same dermo-cosmetic consumer.

Regional players

• Julphar (Gulf Pharmaceutical Industries): UAE-based pharmaceutical manufacturer with dermatology, consumer health, and generic Rx products distributed across the Middle East and Africa. Comparable in product mix (Rx + cosmeceutical), regional go-to-market, and reliance on distributor networks in emerging markets.
• Tabuk Pharmaceuticals: Saudi-headquartered pharmaceutical manufacturer producing branded generics including dermatology and consumer health SKUs for MENA markets. Comparable as a regional pharma manufacturer with overlapping product categories and Saudi/GCC distribution, particularly relevant given Derma Pella's 2024 Deef partnership.
• Eva Pharma: Egyptian pharmaceutical manufacturer with a broad branded-generics portfolio including dermatology and consumer healthcare, exporting across MENA and Africa. Comparable as an emerging-market pharma manufacturer competing for the same regional dermatology shelf-space.
• Hikma Pharmaceuticals: Jordan-headquartered multinational pharmaceutical manufacturer with branded generics, injectables, and a growing dermatology/consumer health presence across MENA and the US. Closely comparable as a Jordan-rooted pharma manufacturer expanding internationally through both direct sales and partnerships.
• Dar Al Dawa: Jordanian pharmaceutical manufacturer with a broad branded-generics portfolio including dermatology, sold across MENA. Direct regional peer operating from the same country with overlapping therapeutic categories and distribution channels.
• SPIMACO Addwaeih: Saudi pharmaceutical company manufacturing branded generics across multiple therapeutic areas including dermatology for MENA distribution. Relevant as a regional peer with similar product breadth and GCC-focused go-to-market.

Emerging players

• Glenmark Pharmaceuticals: India-headquartered pharmaceutical company with a sizable dermatology franchise (branded generics and dermo-cosmetics) exporting to emerging markets including MENA and Africa. Comparable as an emerging-market dermatology exporter competing for the same distributor relationships and price-sensitive pharmacy channels.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/Dermapharma
• LinkedInlinkedin.com/company/pella-pharmaceuticals-co

Compliance8 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Derma Pella Pharmaceuticals